U.S. IBD Treatment Market Size & Trends
The market for treating inflammatory bowel disease in the United States was estimated at 13.12 billion USD in 2024 and is expected to grow at a 2.7% CAGR from 2025–2030. The growing adoption of advanced therapeutic options such as biologics, JAK inhibitors, and individualized treatment strategies for managing Crohn's disease and ulcerative colitis is driving the market. Over the forecast period, market expansion is expected to be driven by increasing awareness, new drug formulations, and supportive reimbursement systems.
The increasing prevalence of Inflammatory Bowel Disease (IBD) in the United States is driving the market for treatments for IBD. For instance, the Crohn's & Colitis Foundation reported that by November 2024, well over 3 million Americans were living with IBD. Over 100,000 American youth under 20 currently suffer from IBD, a number that has been steadily rising since 2020. This data indicates that there is a growing pool of pediatric patients. According to a recent study published in 2023, IBD incidence is rising, particularly among younger people. This raises the demand for early and advanced intervention therapies.
The USA Market has seen significant advancements in biologic therapies, which have provided better treatment options for patients with inflammatory bowel disease (IBD). For instance, in June 2022, the FDA approved Risankizumab (Skyrizi), a monoclonal antibody designed for moderate-to-severe Crohn's disease, representing a major advancement in targeted therapy. Skyrizi joins a growing class of biologics that works by interrupting specific immune pathways to reduce intestinal inflammation. Other biological therapeutics include vedolizumab (Entyvio) and Ustekinumab (Stelara), which have been shown to be highly effective and have favorable safety profiles. Clinical practice prefers them because they can achieve remission with fewer systemic side effects. Consequently, biologics are being adopted more and more, changing IBD management all over the country.
We expect the US IBD market to prioritize individualized and preventive care. Microbiome-based therapies have the potential to rebalance gut flora and decrease inflammation. Gene therapies and stem cell techniques could provide long-term disease control or potential cures. Remote monitoring and real-time symptom tracking digital platforms are likely to grow.
Market Concentration & Characteristics
The U.S. Inflammatory Bowel Disease (IBD) treatment market is marked by a high degree of innovation, with leading players like Biogen, Novartis AG, Eli Lilly and Company, and Johnson & Johnson Services, Inc. investing heavily in the development of next-generation biologics and small-molecule therapies. Advancements include better monoclonal antibodies that target diseases more precisely and cause fewer immune reactions, along with the investigation of oral JAK inhibitors and S1P modulators to make it easier for patients to stick to their treatment.
The U.S. IBD treatment market poses substantial entry barriers, particularly for new or smaller biopharma companies. Developing biologics like monoclonal antibodies or biosimilars demands extensive R&D infrastructure, high capital investment, and regulatory expertise. CELLTRION INC., known for its biosimilar portfolio, faces regulatory and commercial challenges in establishing clinical equivalence and safety in a highly scrutinized market. Manufacturing consistency, especially for biologics, is critical, necessitating robust quality assurance systems.
The FDA and EMA enforce rigorous regulatory frameworks for IBD treatments, especially for biologics and novel small-molecule drugs. Regulatory requirements involve detailed safety and effectiveness information for people with Crohn’s Disease and Ulcerative Colitis, and often need ongoing monitoring and plans to manage risks after the drugs are on the market. Eli Lilly and UCB S.A., both advancing innovative immunology therapies, must align clinical protocols with strict endpoints and trial designs to secure approval.
IBD therapies face substitution pressure from biosimilars and alternative mechanisms of action. For instance, CELLTRION INC. offers infliximab biosimilars as cost-effective options, potentially disrupting originator products. Oral medications like JAK inhibitors and S1P receptor modulators are easier to take than intravenous or subcutaneous biologics, especially for moderate to severe cases. However, these substitutes vary in safety profiles, with some posing risks such as thromboembolism or immunosuppression. Treatment decisions are increasingly guided by therapeutic response monitoring and patient lifestyle considerations, shifting the market toward a more personalized approach.
Companies like Novartis AG and UCB S.A. are strategically expanding their IBD portfolios beyond the U.S., targeting high-growth regions such as Asia-Pacific and Latin America, where IBD incidence is rising due to urbanization and dietary changes. Leveraging partnerships for localized production and regulatory navigation, these companies aim to reduce treatment costs and improve access. In the U.S., distribution channels are evolving, with a shift toward specialty pharmacies and integrated delivery networks that streamline biologics administration and follow-up. Digital health tools and remote monitoring are also enhancing patient engagement and adherence.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Type Insights
The Crohn's disease segment held the largest market share, driven by the growing demand for advanced treatment options and the availability of therapies such as biologics and JAK inhibitors. The increasing prevalence of Crohn's disease and ongoing research into more effective therapies are expected to sustain the segment's dominant position throughout the forecast period.
On the other hand, the ulcerative colitis segment is anticipated to register the fastest CAGR of 3.5% over the forecast period. This can be attributed to the increasing adoption of biologics and targeted therapies to treat ulcerative colitis. The rising prevalence of the disease and advancements in treatment options are expected to drive the segment's growth further.
Drug Class Insights
The TNF inhibitors segment held the largest market share of 62.0%) in 2024. This can be attributed to the well-established efficacy of TNF inhibitors in treating IBD, particularly in managing inflammation and inducing disease remission. The segment benefits from a strong clinical foundation and continued advancements in the formulation and delivery of these drugs. In addition, the widespread use of TNF inhibitors in both Crohn's disease and ulcerative colitis contributes significantly to their dominant market position.
The JAK inhibitors segment is projected to grow at a significant CAGR over the forecast period. JAK inhibitors have emerged as a key therapeutic option in the treatment landscape for inflammatory bowel disease (IBD), especially for patients with moderate to severe ulcerative colitis and Crohn’s disease. These small pills work by targeting Janus kinase (JAK) pathways, which control the activity of certain substances that cause inflammation in IBD. By modulating these pathways, JAK inhibitors reduce systemic and localized inflammation, helping achieve and maintain disease remission. Their oral administration offers an advantage in patient convenience compared to biologic injectables, especially for those with inadequate response to conventional therapies.
Route Of Administration Insights
The injectable segment dominated the market with a 92.00% share in 2024. This can be attributed to the widespread use of biologics and biosimilars, which offer effective treatment for IBD, such as Crohn's disease and ulcerative colitis. The injectable route provides systemic treatment, allowing the medication to circulate throughout the body and directly target inflamed areas.
The oral segment is projected to grow at the fastest CAGR over the forecast period, driven by the increasing preference for convenient, non-invasive treatment options. Oral therapies, such as JAK inhibitors, are gaining popularity due to their ease of use, reducing the need for injections and improving patient adherence to treatment regimens.
Distribution Channel Insights
The hospital pharmacies segment held the largest revenue share of 46.65% in 2024 due to their significant role in the administration of specialized treatments for IBD, such as Crohn’s disease and ulcerative colitis. Hospital pharmacies are integral in managing complex medication regimens and providing tailored care for IBD patients.
The online pharmacy segment is expected to register the fastest CAGR over the forecast period. This growth can be attributed to the increasing adoption of digital platforms, the convenience they offer patients to access treatments, and the growing trend of home delivery services for medications, especially for chronic conditions like IBD.
Regional Insights
West U.S. Inflammatory Bowel Disease Treatment Market Trends
The Western U.S. remains a key region in IBD treatment innovation, driven by the presence of major biotechnology hubs and academic research centers in California and Washington. Companies like Gilead Sciences, Genentech (a member of the Roche Group), and Biogen leverage these ecosystems to conduct cutting-edge clinical trials and accelerate new product development.
Midwest U.S. Inflammatory Bowel Disease Treatment Market Trends
The Midwest U.S. showcases a stable and growing IBD treatment landscape supported by strong healthcare systems and academic partnerships in states like Illinois, Minnesota, and Ohio. Companies such as Johnson & Johnson (Stelara, Remicade) and CELLTRION INC. actively participate in real-world studies and biosimilar introduction.
Northeast U.S. Inflammatory Bowel Disease Treatment Market Trends
The Northeast, home to renowned medical institutions and pharmaceutical giants like Merck & Co., Inc. and Eli Lilly, is at the forefront of adopting personalized IBD treatment strategies. There is a strong emphasis on specific treatments, such as IL inhibitors and JAK inhibitors, which are often used together to treat difficult cases of Crohn’s Disease and Ulcerative Colitis.
Southwest U.S. Inflammatory Bowel Disease Treatment Market Trends
The Southwest U.S., including states like Texas and Arizona, is witnessing rising IBD prevalence due to demographic shifts and improved diagnostic rates. UCB S.A. and Novartis AG are expanding their market presence here through targeted outreach and payer collaborations.
Southeast U.S. Inflammatory Bowel Disease Treatment Market Trends
The Southeast U.S. is emerging as a significant market for IBD treatments, with increasing disease awareness, improved access to gastroenterologists, and expanding healthcare infrastructure. Biogen and CELLTRION INC. are key players driving biosimilar penetration in this cost-sensitive market. While aminosalicylates and corticosteroids remain staples in initial treatment, biologics-especially TNF inhibitors and IL inhibitors-are being increasingly integrated into treatment protocols for patients with moderate-to-severe diseases.
Key U.S. Inflammatory Bowel Disease Treatment Company Insights
Key players in the Inflammatory Bowel Disease (IBD) treatment market include Biogen, Novartis AG, Eli Lilly and Company, UCB S.A., CELLTRION INC., Merck & Co., Inc., and Johnson & Johnson Services, Inc. These companies focus on strategies such as mergers and acquisitions, collaborations, and developing new products to strengthen their market presence.
-
Landos Biopharma is working on NX-13, a new oral medication that targets the NLRX1 pathway to help control the immune response in inflammatory bowel disease. NX-13 is made to be safer and easier to tolerate, and early tests for ulcerative colitis have shown positive signs in how it affects certain biological markers and clinical outcomes. The company’s novel approach offers a differentiated mechanism from existing biologics, positioning NX-13 as a potential maintenance therapy with fewer immunosuppressive risks.
-
MorphoSys AG is working with Incyte to create guselkumab, which is an IL-23 inhibitor, for treating Crohn’s Disease and Ulcerative Colitis. Although originally developed for psoriasis, IL-23 inhibitors are now being repositioned in IBD with promising efficacy and improved dosing convenience. Guselkumab's Phase II/III IBD trials aim to validate its utility in biologic-experienced patient populations.
-
Precision IBD (a Takeda-backed company)Precision IBD is working on leveraging AI-driven diagnostics and targeted therapies to personalize treatment for IBD patients. Their research platforms aim to find different types of IBD at a molecular level to help choose the best treatment, particularly for patients with Crohn’s Disease or Ulcerative Colitis that don't respond to standard treatments. This precision medicine approach could revolutionize IBD management by reducing trial-and-error prescribing and improving long-term outcomes.
Key U.S. Inflammatory Bowel Disease Treatment Companies
- Biogen
- Novartis AG
- Eli Lilly and Company
- UCB S.A.
- CELLTRION INC
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
Recent Developments
-
In April 2024, Celltrion Inc. USA expanded access to ZYMFENTRA (infliximab-dyyb) in the U.S. through a collaboration with Cigna Healthcare and Express Scripts, making the subcutaneous infliximab available to over 16 million insured lives. This partnership enhances patient access to an innovative and convenient treatment option for moderate to severe ulcerative colitis and Crohn’s disease, focusing on patient safety and monitoring protocols.
-
In March 2025, Johnson & Johnson Services, Inc. got approval from the U.S. FDA for TREMFYA (guselkumab), which is the first IL-23 inhibitor that can be given as an injection or through an IV, to treat adults with moderate to severe Crohn’s disease (CD). This approval expands treatment options for nearly three million Americans living with IBD.
-
In March 2025, Johnson & Johnson Services, Inc. launched a newly FDA-approved dual-acting monoclonal antibody therapy for moderate to severe ulcerative colitis (UC) in the U.S. In clinical trials, this therapy demonstrated significant symptom improvement and intestinal healing, marking a major advancement in IBD treatment.
U.S. Inflammatory Bowel Disease Treatment Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 13.72 billion |
|
Revenue forecast in 2030 |
USD 15.70 billion |
|
Growth rate |
CAGR of 2.7% from 2025 to 2030 |
|
Actual data |
2018-2024 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
|
Segments covered |
Type, drug class, route of administration, distribution channel, and region |
|
Country scope |
U.S. |
|
Key companies profiled |
Biogen; Novartis AG; Eli Lilly and Company; UCB S.A.; CELLTRION INC; Merck & Co., Inc.; Johnson & Johnson Services, Inc. |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Changes or additions to the scope of the country, region, and segment are possible. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
U.S. Inflammatory Bowel Disease Treatment Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the subsegments from 2018 to 2030. For this study, MIR has segmented the U.S. market report on inflammatory bowel disease treatment based on type, drug class, route of administration, distribution channel, and region
-
Type Outlook (Revenue, USD Million, 2018-2030)
-
Crohn's Disease
-
Ulcerative Colitis
-
-
Drug Class Outlook (Revenue, USD Million, 2018-2030)
-
Aminosalicylates
-
Corticosteroids
-
TNF inhibitors
-
IL inhibitors
-
Anti-integrin
-
JAK inhibitors
-
Others
-
-
Route of Administration Outlook (Revenue, USD Million, 2018-2030)
-
Oral
-
Injectable
-
-
Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
-
-
Regional Outlook (Revenue, USD Million, 2018-2030)
-
West
-
Midwest
-
Northeast
-
Southwest
-
Southeast
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy